VectorY secures €30 million EIB loan to accelerate neurodegenerative disease treatments
Amsterdam-based VectorY Therapeutics receives €30 million from the European Investment Bank under the InvestEU programme to advance treatments for ALS and Huntington’s disease.
VectorY Therapeutics, an Amsterdam-based biotechnology company, has secured a €30 million convertible loan from the European Investment Bank (EIB) to advance the development of treatments for neurodegenerative diseases, including ALS and Huntington’s disease.
The financing, announced in an EIB press release, is supported by the European Commission’s InvestEU programme. This initiative aims to foster innovation and competitiveness across the EU, with the InvestEU Fund backed by a €29.1 billion EU budget guarantee and expected to mobilize up to €427 billion in additional investment.
VectorY’s proprietary platform utilizes vectorised antibodies, designed to address treatment limitations for neurodegenerative conditions that currently lack effective therapies. The EIB’s support is expected to accelerate the company’s pipeline, potentially improving outcomes for patients suffering from some of the most challenging neurological disorders.
For Europe, this investment aligns with broader efforts to strengthen the region’s position in the global health market. The Netherlands, which holds a 5.2% stake in the EIB, has benefited from €36 billion in EIB-backed financing for national projects, underscoring the country’s active role in European innovation.
The initiative comes amid rising competition in the biotech sector targeting neurodegenerative diseases. The EIB notes that the loan to VectorY addresses both a significant market gap and a public health need, while also supporting the expansion of the company’s treatment pipeline.
Clinical advancement of VectorY’s therapies remains subject to the inherent risks of drug development, including regulatory hurdles and market competition. However, the EIB’s backing reflects confidence in the company’s approach and the potential of EU funding to catalyse innovative health solutions.
For investors and policymakers, the deal highlights the strategic importance of public financial support in advancing breakthrough biotech innovations within Europe.
